Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls by Correll, Christoph U et al.
Prevalence, incidence and mortality from cardiovascular disease in
patients with pooled and speciﬁc severe mental illness: a large-scale
meta-analysis of 3,211,768 patients and 113,383,368 controls
Christoph U. Correll1-5, Marco Solmi5-7, Nicola Veronese5, Beatrice Bortolato5,8, Stella Rosson6, Paolo Santonastaso6, Nita Thapa-Chhetri9,
Michele Fornaro10, Davide Gallicchio6, Enrico Collantoni6, Giorgio Pigato6, Angela Favaro6, Francesco Monaco5, Cristiano Kohler11,
Davy Vancampfort12,13, Philip B. Ward14, Fiona Gaughran15, Andre F. Carvalho5,11, Brendon Stubbs5,15-17
1Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; 2Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medi-
cine, Hempstead, NY, USA; 3Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; 4Department of Psychiatry and Behavioral
Medicine, Albert Einstein College of Medicine, Bronx, NY, USA; 5Institute for Clinical Research and Education in Medicine, Padua, Italy; 6Department of Neurosciences, Univer-
sity of Padua, Padua, Italy; 7Mental Health Department, Local Health Unit 17, Padua, Italy; 8Mental Health Department, Local Health Unit 10, Portogruaro, Italy; 9University of
Connecticut Health Center, Farmington, CT, USA; 10New York Psychiatric Institute, Columbia University, New York, NY, USA; 11Department of Clinical Medicine and Transla-
tional Psychiatry Research Group, Federal University of Ceara, Fortaleza, Brazil; 12KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium; 13KU Leuven University
Psychiatric Center, Leuven-Kortenberg, Belgium; 14School of Psychiatry, University of New South Wales, Sydney, Australia; 15South London and Maudsley, NHS Foundation
Trust, London, UK; 16Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 17Depart-
ment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular dis-
ease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of
CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease;
and CVD-related death in SMI patients (N53,211,768) versus controls (N5113,383,368) (92 studies). The pooled CVD prevalence in SMI
patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had signiﬁcantly higher odds
of CVD versus controls in cross-sectional studies (odds ratio, OR51.53, 95% CI: 1.27-1.83; 11 studies), and higher odds of coronary heart dis-
ease (OR51.51, 95% CI: 1.47-1.55) and cerebrovascular disease (OR51.42, 95% CI: 1.21-1.66). People with major depressive disorder were at
increased risk for coronary heart disease, while those with schizophrenia were at increased risk for coronary heart disease, cerebrovascular dis-
ease and congestive heart failure. Cumulative CVD incidence in SMI patients was 3.6% (95% CI: 2.7-5.3) during a median follow-up of 8.4
years (range 1.8-30.0). Adjusting for a median of six confounders, SMI patients had signiﬁcantly higher CVD incidence than controls in longi-
tudinal studies (hazard ratio, HR51.78, 95% CI: 1.60-1.98; 31 studies). The incidence was also higher for coronary heart disease (HR51.54,
95% CI: 1.30-1.82), cerebrovascular disease (HR51.64, 95% CI: 1.26-2.14), congestive heart failure (HR52.10, 95% CI: 1.64-2.70), and CVD-
related death (HR51.85, 95% CI: 1.53-2.24). People with major depressive disorder, bipolar disorder and schizophrenia were all at increased
risk of CVD-related death versus controls. CVD incidence increased with antipsychotic use (p50.008), higher body mass index (p50.008) and
higher baseline CVD prevalence (p50.03) in patients vs. controls. Moreover, CVD prevalence (p50.007), but not CVD incidence (p50.21),
increased in more recently conducted studies. This large-scale meta-analysis conﬁrms that SMI patients have signiﬁcantly increased risk of
CVD and CVD-related mortality, and that elevated body mass index, antipsychotic use, and CVD screening and management require urgent
clinical attention.
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People with severe mental illness (SMI) – including schizo-
phrenia, bipolar disorder, major depressive disorder, and their
related spectrum disorders – have a life expectancy shortened
of 10-17.5 years compared to the general population1,2. While
suicide explains some of this reduced life expectancy3, it is
now established that physical diseases account for the over-
whelming majority of premature mortality4,5. Among physical
conditions, cardiovascular disease (CVD) is the main potentially
avoidable contributor to early deaths in patients with SMI4.
Given the importance of understanding the magnitude,
contributors to and relative distribution of CVD risk in people
with SMI, a number of disease-speciﬁc meta-analyses investi-
gated if people with major depressive disorder, bipolar disor-
der or schizophrenia are at an increased risk of CVD compared
to controls. These meta-analyses reported that people with
depression (deﬁned by the presence of depressive symptoms
or a diagnosis of major depressive disorder) are at increased
CVD risk6,7, including stroke (risk ratio, RR51.34, 95% CI:
1.17-1.54), myocardial infarction (hazard ratio, HR51.31, 95%
CI: 1.09-1.57), coronary heart disease (RR51.36, 95% CI:
1.24-1.49) and coronary heart disease-related death (HR51.36,
95% CI: 1.14-1.63)6-8. While clearly informative, results concern-
ing CVD were not speciﬁc for major depressive disorder deﬁned
according to established diagnostic criteria, possibly biasing
such observed association towards a lower risk9. Another
meta-analysis of longitudinal studies, which utilized standard-
ized criteria to deﬁne bipolar disorder, reported mixed results,
since people with that disorder were actually not at increased
risk of myocardial infarction (RR51.09, 95% CI: 0.96-1.24),
whereas the risk of stroke was higher compared to controls
(RR51.74, 95% CI: 1.29-2.35)10. Among individuals with schiz-
ophrenia, previous meta-analyses11,12 reported an overall
increased risk of CVD compared to controls (RR51.53, 95% CI:
1.27-1.86). This risk increase included stroke (up to RR51.71,
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95% CI: 1.19-2.46) and heart failure (RR51.81, 95% CI: 1.42-2.29),
but not coronary heart disease (RR51.20, 95% CI: 0.93-1.53).
While the existing literature has provided relevant insights,
several limitations are to be highlighted and important questions
remain unanswered. First, some of the previous meta-analyses
did not use standardized clinical assessments to identify and
categorize SMI and/or cardiovascular events. Second, the exact
prevalence and incidence of each type of CVD among people
with SMI, both within and across major diagnostic SMI sub-
groups, remains unclear. Third, the magnitude of premature
CVD-related mortality risk in people with SMI versus controls
is to be speciﬁed. Fourth, potential risk factors for increased
CVD and related mortality risk across the SMI groups have not
been elucidated via meta-analytic techniques, which could
help identify targets for treatment guidelines, clinical stand-
ards and development of preventive and therapeutic pro-
grams. In this regard, large-scale pooled analyses in the SMI
population can provide relevant information, allowing the
investigation of potentially shared risk factors across many
studies and participants, thus dissecting CVD risk factors asso-
ciated with SMI and/or treatments for these disorders from
factors which are non-speciﬁc or shared with the general pop-
ulation13. Additionally, pooling of data allows for the investiga-
tion of demographic, regional and treatment variables, both
within and across major diagnostic categories.
Given the caveats mentioned above, the current gaps within
the literature and the need to better understand CVD risk among
people with SMI, we conducted a large scale meta-analysis
investigating the prevalence, incidence and mortality attributed
to CVD and their correlates among people with SMI, both
within and across major diagnostic groups.
METHODS
This systematic review and meta-analysis adhered to the
PRISMA statement14, following a predetermined, but unpub-
lished protocol.
Search strategy
An electronic literature search was conducted in PubMed,
Embase and Scopus from database inception until August 2,
2016 by two independent reviewers, using the search terms
(“bipolar disorder” ORmania OR schizophrenia OR schizoaffec-
tive OR psychosis OR “major depression” OR “serious mental
illness”) AND (cardiovascular OR stroke OR cerebrovascular OR
“transient ischemic attack” OR “transient ischaemic attack” OR
“peripheral vascular” OR “myocardial infarction” OR “coronary
heart disease” OR” coronary artery disease” OR “ischemic heart
disease” OR “ischaemic heart disease” OR “hypertensive heart
disease” OR angina OR “cardiac failure” OR “heart failure” OR
“congestive heart failure” OR “atrial ﬁbrillation” OR “pulmonary
embolism” OR “cardiovascular mortality”). Furthermore, bibli-
ographies of included papers were reviewed.
Inclusion and exclusion criteria
We included studies with the following characteristics: a)
reporting on patients with schizophrenia, schizophrenia spec-
trum or schizoaffective disorder, bipolar disorder or bipolar
spectrum disorders, major depressive disorder or depressive
episodes, or SMI (deﬁned as at least two among major depres-
sive spectrum, bipolar spectrum and schizophrenia spectrum
disorders) according to DSM-III, DSM-IV, DSM-5, ICD-8, ICD-
9 or ICD-10, or a medical record diagnosis based on a clinical
interview; b) having a cross-sectional or a retrospective/
prospective longitudinal design, either with or without a control
group; c) using a standardized deﬁnition of CVD; d) reporting RR,
HR or odds ratio (OR) comparing patients with region-speciﬁc
controls, percentage or number of events at baseline (data used
for cross-sectional analysis5prevalence) and/or follow-up (data
used for longitudinal analysis5 cumulative incidence).
We excluded studies that investigated cardiovascular risk
estimates and/or factors, subclinical CVD, or SMI rates in pop-
ulations with CVD. In case of multiple publications from the
same study, only the most recent paper or the article with the
longest follow-up was included. When required, we contacted
the primary/corresponding authors of potential studies to
conﬁrm eligibility or acquire unpublished variables of interest.
Data extraction
Seven authors divided in four pairs independently extracted
data in a standardized Microsoft Excel sheet, with reciprocal
validation of data extraction results. The extracted data includ-
ed: authors, year and country; geographic region; study design;
data source; period of data collection; SMI diagnostic criteria;
CVD diagnostic criteria; speciﬁc SMI and CVD diagnosis; case
and control inclusion criteria; number of cases and controls;
percentage or number with CVD, coronary heart disease, cere-
brovascular disease and congestive heart failure at baseline;
number of events at follow-up; follow-up duration; number
and type of covariates considered in the analyses; OR, RR, rate
ratio and HR with their respective 95% upper and lower CIs;
mean age with standard deviation; mean body mass index
with standard deviation; proportion of males; co-occurring
obesity, alcohol and substance related disorders, diabetes,
hypertension, and hyperlipidemia; married status; employ-
ment status; percentage of patients with poorest income and
least urbanized; and percentage of patients taking antipsy-
chotics. Rate ratios calculated with Cox regression models
were included in HR analyses. When authors did not specify
whether or not a rate ratio had been calculated with Cox
regression models, we contacted them seeking clariﬁcation.
Outcomes
Primary outcomes were CVD prevalence and cumulative
incidence plus CVD-related mortality in people with SMI, as
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well as adjusted OR for prevalence and HR for incidence rates
in SMI versus controls. Secondary outcomes were the same
measures for speciﬁc CVDs (i.e., coronary heart disease, cere-
brovascular disease, congestive heart failure) in SMI patients,
as well as adjusted OR and HR versus controls.
Prevalence and OR were calculated from cross-sectional
studies and from baseline results of longitudinal studies.
Where available, incidence, RR and HR were calculated from
longitudinal studies.
Quality assessment
For the purpose of this meta-analysis, a checklist (yes versus
no) was used to assess the methodological quality of included
studies. The evaluation of methodological quality across stud-
ies was based on the following factors: clear diagnostic criteria,
presence of a control group, matching of the control group,
covariate-adjusted outcomes, reported cardiovascular risk fac-
tors at baseline, and follow-up 5 years.
Data analysis
This meta-analysis was performed using Comprehensive
Meta-Analysis V315. All outcomes were meta-analyzed when at
least two studies provided data. A random effects model16,17
was used to account for between-study heterogeneity. We cal-
culated pooled CVD prevalences and pooled CVD cumulative
incidences, each with SMI subgrouping. For dichotomous pri-
mary and secondary outcomes comparing pooled SMI and
SMI subgroups with controls, we calculated unadjusted as
well as adjusted pooled OR for cross-sectional data, and unad-
justed pooled RR, as well as adjusted pooled HR, for longitudi-
nal data. Funnel plots were visually inspected, and Egger’s
test18 and Begg-Mazumdar Kendall’s tau19 were used to deter-
mine if publication bias was likely. When publication bias was
present, the trim and ﬁll20 procedure was run to evaluate if the
results changed after imputing potentially missing studies.
Between-study heterogeneity was measured using the chi-
squared and I-squared statistics, with chi-squared p<0.05 and
I-squared 50% indicating signiﬁcant heterogeneity21. To iden-
tify potential moderators, meta-regression was run with Com-
prehensive Meta-Analysis V3 for unadjusted outcomes where
heterogeneity was signiﬁcant.
Since CVD rates in the general population vary across the
world, we also performed a stratiﬁed analysis across geograph-
ic regions (Asia, Europe, North America, Oceania) regarding
raw CVD prevalence and incidence in SMI populations, and
compared patients to their respective region-speciﬁc general
population controls (calculating RRs as well as adjusted ORs
and HRs for the four regional strata and comparing them
across the different regions whenever at least two studies pro-
vided data per each region).
The following study and patient characteristics were explor-
ed as potential moderators and mediators in addition to SMI
status: geographical region of the sample; time of data collec-
tion; percentage of patients taking antipsychotics; and the dif-
ference between patient and control samples regarding age,
body mass index, proportion of males and of those with married
status, unemployed, with poorest income, least urbanized, and
having co-occurring obesity, alcohol and substance-related dis-
orders, diabetes, hypertension or hyperlipidemia.
RESULTS
Search results
Out of 18,064 initial hits across the searched electronic
databases, 11,878 unduplicated hits were screened, and 11,576
were excluded through title/abstract reading. Altogether, 302
full texts were reviewed, and 210 were excluded with speciﬁc
reasons. Among 92 studies meeting inclusion criteria, 27 had a
cross-sectional design22-48 and 65 studies had a retrospective
or prospective longitudinal design49-113 (Figure 1).
Characteristics of included studies
We included 92 studies, with a total population of 3,211,768
patients (mean age 50 years, 49% male) with SMI and
113,383,368 controls (mean age 51 years, 49% male), with a total
of 116,595,136 subjects when summing those studies where
patient and control sample sizes were not separately reported.
Altogether, 27 studies (N527,037,943) were cross-sectional and
65 studies (N589,557,193) were longitudinal. Overall, 38 studies
included patients with schizophrenia (of which 29 were longitu-
dinal), 30 with bipolar disorder (21 longitudinal), 30 with major
depressive disorder (22 longitudinal), and 14 with SMI (8 longitu-
dinal). Taken together, six studies included only patients with
SMI (N5884,412), 16 studies included only patients with bipolar
disorder (N571,832), 20 studies included only patients with
major depressive disorder (N5111,360), and 29 studies includ-
ed only patients with schizophrenia (N51,591,106), while 19
studies included different subgroups of SMI, providing data for
each of them separately (some studies included more than
one diagnostic group, see Tables 1 and 2 for details).
Meta-analysis: cross-sectional results
The pooled CVD prevalence in SMI was 9.9% (95% CI: 7.4-13.3;
38 studies). Individual rates were 8.4% for people with bipolar
disorder (95% CI: 5.4-12.6, 12 studies, N566,911); 11.7% for
those with major depressive disorder (95% CI: 3.6-32.2, 7 stud-
ies, N583,965); 11.8% for those with schizophrenia (95% CI:
7.1-19.0, 13 studies, N5191,982), and 11.8% for those with SMI
(95% CI: 4.1-29.4, 6 studies, N517,286) (p<0.001 for SMI diag-
nostic subgroup comparisons).
Adjusting for a median of seven potential confounders, the
adjusted pooled OR for CVD in SMI compared to controls was
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1.53 (95% CI: 1.27-1.83, p<0.001, 11 studies). For speciﬁc
CVDs, pooled together, people with SMI had an increased risk
of coronary heart disease (OR51.51, 95% CI: 1.47-1.55,
p<0.001, 5 studies) and cerebrovascular disease (OR51.42,
95% CI: 1.21-1.66, p<0.001, 6 studies), with a strong statistical
trend for congestive heart failure (OR51.28, 95% CI: 0.99-1.65,
p50.06, 4 studies). Considering separately single types of SMI
and CVD, in adjusted OR analyses, bipolar disorder was not
signiﬁcantly associated with CVD or its subtypes; major
depressive disorder was signiﬁcantly associated with CVD and
coronary heart disease; and schizophrenia was signiﬁcantly
associated with coronary heart disease, cerebrovascular dis-
ease and congestive heart failure (Table 3). No adjusted ORs
were available for mixed SMI groups.
All signiﬁcant results were signiﬁcantly heterogeneous. After
adjusting for publication bias with the trim-and-ﬁll method, all
pooled previously signiﬁcant ORs remained statistically signiﬁ-
cant, conﬁrming the association of CVD, coronary heart disease
and cerebrovascular disease with SMI, while the OR for conges-
tive heart failure becamemarginally signiﬁcant (p50.05).
Meta-analysis: longitudinal adjusted results
Among patients with SMI, 3.6% (95% CI: 2.7-5.3%) experi-
enced a CVD event during a median follow-up period of 8.4
years (range 1.8-30.0) (65 studies). After adjusting for a median
of six potential confounders, people with SMI were at signiﬁ-
cantly increased risk across longitudinal studies for CVD
(HR51.78, 95% CI: 1.60-1.98) (31 studies, N5671,384 cases vs.
N514,335,203 controls) as well as for speciﬁc CVDs, including
coronary heart disease (HR51.54, 95% CI: 1.30-1.82, 18 studies,
N5194,017 cases vs. N513,530,858 controls), cerebrovascular
Figure 1 PRISMA ﬂow chart
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disease (HR51.64, 95% CI: 1.26-2.14, 11 studies, N5188,841
cases vs. N513,113,564 controls), congestive heart failure
(HR52.10, 95% CI: 1.64-2.70, 2 studies, N5409 cases vs.
N541,678 controls), peripheral vascular disease (only unad-
justed RR53.11, 95% CI: 2.46-3.91, three studies), and CVD-
related death (HR51.85, 95% CI: 1.53-2.24, 16 studies, N5353,407
cases vs. N57,317,053 controls).
According to adjusted HRs, schizophrenia was signiﬁcantly
associated with CVD in longitudinal studies (HR51.95, 95%
CI: 1.41-2.70, 14 studies), as well as with coronary heart dis-
ease (HR51.59, 95% CI: 1.08-2.35, 5 studies), cerebrovascular
disease (HR51.57, 95% CI: 1.09-2.25, 5 studies), and CVD-
related death (HR52.45, 95% CI: 1.64-3.65, 9 studies).
According to adjusted HRs, bipolar disorder was signiﬁcant-
ly associated with CVD in longitudinal studies (HR51.57, 95%
CI: 1.28-1.93, 10 studies) as well as with CVD-related death
(HR51.65, 95% CI: 1.10-2.47, 3 studies), with a trend toward a
signiﬁcant association with cerebrovascular disease (HR51.60,
95% CI: 0.99-2.57, 4 studies), but no signiﬁcant association
with coronary heart disease (HR51.16, 95% CI: 0.76-1.78, 4
studies). One study reported a signiﬁcant association with
congestive heart failure (HR5 2.27, 95% CI: 1.49-3.45).
According to adjusted HRs, major depressive disorder was
signiﬁcantly associated with CVD in longitudinal studies
(HR51.72, 95% CI: 1.48-2.00, 18 studies) as well as with coro-
nary heart disease (HR51.63, 95% CI: 1.33-2.00, 9 studies),
cerebrovascular disease (HR52.04, 95% CI: 1.05-3.96, 3 stud-
ies), congestive heart failure (HR52.02, 95% CI: 1.48-2.75, 2
studies), and CVD-related death (HR51.63, 95% CI: 1.25-2.13,
7 studies).
According to adjusted HRs, mixed SMIs were signiﬁcantly
associated with CVD in longitudinal studies (HR53.24, 95%
Table 1 Cross-sectional studies: characteristics of included studies and samples
Study Country
No.
cases
No.
controls
Period of
data collection SMI deﬁnition Inclusion criteria for cases
No.
covariates
Beyer et al22 USA 1,379 - 2001-2002 Medical records Bipolar disorder -
Bresee et al23 Canada 28,775 2,281,636 1995-2006 ICD-9,10 Schizophrenia 4
Bresee et al24 Canada 399 120,044 2005 Medical records Schizophrenia 11
Chen et al25 Taiwan 80 - 2015 DSM-IV Bipolar disorder, >60 years -
Curkendall et al26 Canada 3,022 12,088 1994-1999 ICD-9 Schizophrenia 7
Devantier et al27 Denmark 28 27 2009-2011 ICD-10 Major depressive disorder, late onset -
Hagg et al28 Sweden 269 - 2000-2003 DSM-IV Schizophrenia, 20-69 years -
Herbst et al29 USA 10,573 total population 2001-2002 DSM-IV Major depressive disorder, >60 years 11
Huang et al30 Taiwan 117,987 21,356,304 2000-2003 ICD-9 Bipolar disorder or major depressive disorder 1
Hyde et al31 Australia 355 - 2008-2012 Medical records Severe mental illness, prescribed clozapine -
Kilbourne et al32 USA 8,083 - 2001 ICD-9 Severe mental illness, >60 years -
Kilbourne et al33 USA 9,705 5,353 2000-2001 ICD-9 Bipolar disorder or severe mental illness, male 3
Lindegard34 Sweden 368 87,176 1966-1979 ICD-9, DSM-III Major depressive disorder or bipolar disorder -
Maina et al35 Italy 185 - 2006-2008 DSM-IV Severe mental illness -
Morden et al36 Canada 65,362 65,362 2000-2007 ICD-9 Schizophrenia 4
Munoli et al37 India 120 - 2011 ICD-10 Bipolar disorder -
Nielsen et al38 Denmark 937 - 1969-2014 ICD-10 Schizophrenia -
Niranjan et al39 USA 5,695 34,979 2007 DSM-IV Major depressive disorder 6
Oreski et al40 Croatia 289 192 2011 ICD-10 Bipolar disorder or schizophrenia -
Prieto et al41 USA 988 - 2009-2013 DSM-IV Severe mental illness -
Scherrer et al42 USA 628 6,903 1990-1992 DSM-III Major depressive disorder, male twins -
Scott et al43 Multicenter 52,095 total population 2001-2011 DSM-IV Bipolar disorder or major depressive disorder 6
Shen et al44 Taiwan 203 2,036 2005-2007 ICD-9 Schizophrenia, in intensive care unit 6
Smith et al45 UK 9,677 1,414,701 2007 Medical records Schizophrenia 3
Smith et al46 UK 2,582 1,421,796 2007 Medical records Bipolar disorder 2
Swain et al47 Multicenter 45,288 total population 2001-2011 DSM-IV Bipolar disorder or major depressive disorder 7
Zilkens et al48 Australia 656 349 2000-2009 ICD-8,9,10 Major depressive disorder, 65-84 years,
developing dementia
-
SMI – severe mental illness
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Table 2 Longitudinal studies: characteristics of included studies and samples
Study Country
No.
cases
No.
controls
Period of
data collection
SMI
deﬁnition Inclusion criteria for cases
No.
covariates
Almeida et al49 Australia 1,503 35,691 1996-2010 ICD-9 Schizophrenia, bipolar disorder or major
depressive disorder, 65-85 years, male
8
Bremmer et al50 The Netherlands 41 2,080 1992-2000 DSM-III Major depressive disorder, >55 years 13
Butnoriene et al51 Lithuania 184 369 2003-2004 DSM-IV Major depressive disorder, >45 years 4
Callaghan et al52 Canada 5,999 5,999 2002-2006 Medical
records
Bipolar disorder 6
Callaghan et al53 Canada 9,815 9,815 2002-2006 ICD-10 Bipolar disorder 8
Carney et al54 USA 1,074 726,262 1996-2001 ICD-9 Schizophrenia or schizoaffective disorder 4
Chen et al55 Taiwan 63,913 63,913 2002-2008 ICD-9 Schizophrenia 8
Clouse et al56 USA 16 60 1982-1992 DSM-III Major depressive disorder with diabetes 7
Coryell et al57 USA 903 - 1998-1999 RDC Severe mental illness -
Crump et al58 Sweden 6,618 6,580,418 2003-2009 ICD-10 Bipolar disorder 6
Crump et al59 Sweden 8,277 6,097,834 2003-2009 ICD-10 Schizophrenia, >25 years 6
Davis et al60 Hawaii 280 39,000 1999-2005 Medical
records
Major depressive disorder 5
Davydow et al61 Denmark 68,137 5,912,158 1999-2013 ICD-9 Schizophrenia, schizoaffective disorder or
bipolar disorder
5
Enger et al62 USA 1,920 9,600 1995-1999 ICD-9 Schizophrenia, on antipsychotic treatment,
15-64 years
-
Fiedorowicz et al63 USA 288 147 1978-1981 RDC Bipolar disorder 8
Filik et al64 UK 482 1,998 1999-2002 DSM-IV Schizophrenia, schizophreniform or
schizoaffective disorder
6
Fors et al65 Sweden 255 1,275 1981-1991 DSM-II Schizophrenia 3
Gasse et al66 Denmark 873,898 52,693,301 1995-2009 ICD-8,10 Severe mental illness (affective psychoses) 22
Goldstein et al67 USA 5,835 26,266 2001-2005 DSM-IV Bipolar disorder or major depressive disorder 8
Healy et al68 UK 1,429 - 1875-1924;
1994-2010
Medical
records
Schizophrenia -
Hendrie et al69 USA 757 30,831 1999-2008 ICD-9 Schizophrenia, >65 years -
Hou et al70 Taiwan 8,264 - 1985-2008 DSM-III or
IV, ICD-9
Schizophrenia -
Hsieh et al71 Taiwan 9,715 - 2001-2009 ICD-9 Schizophrenia 10
Huang et al72 Taiwan 7,937 31,748 1996-2006 ICD-9 Major depressive disorder 9
Ifteni et al73 Romania 7,189 - 1989-2011 DSM-IV Schizophrenia, inpatients -
Jakobsen et al74 Denmark 74,759 338,747 1977-2000 ICD-8,10 Schizophrenia or major depressive disorder 2
Janszky et al75 Sweden 646 48,675 1969-2007 ICD-8 Major depressive disorder, 18-20 years 7
Jokinen &
Nordstrom76
Sweden 346 - 1980-2005 DSM-IV Major depressive disorder or bipolar disorder -
Joukamaa et al77 Finland 606 8,000 1977-1994 Medical
records
Schizophrenia, mood disorder or severe
mental illness
1
Kendler et al78 Sweden 5,647 24,727 1998-2003 ICD-10 Major depressive disorder, twins -
Kiviniemi et al79 Finland 6,987 - 1998-2003 ICD-9 Schizophrenia, ﬁrst onset -
Lahti et al80 Finland 204 11,880 1969-2004 ICD-8,9,10 Schizophrenia 5
Lan et al81 Taiwan 3,681 - 2001-2006 ICD-9 Bipolar disorder -
Laursen et al82 Denmark 22,294 2,411,852 1995-2007 ICD-8,10 Schizophrenia or bipolar disorder, 15-52
years
3
Laursen et al83 Denmark 1,454 59,256 1995-2006 ICD-8,10 Schizophrenia or bipolar disorder 4
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CI: 2.15-4.88, 3 studies) as well as with CVD-related death
(HR52.75, 95% CI: 1.32-5.73, 3 studies).
All signiﬁcant results were signiﬁcantly heterogeneous,
except for mixed SMI and CVD risk, as well as all the conges-
tive heart failure results. After trim and ﬁll procedure, all
results remained unchanged, and Egger test did not show any
evidence of publication bias inﬂuencing the results (see Table
4 for details).
Quality assessment of included studies
Quality ratings of single studies are presented in Table 5. All
studies used clear diagnostic criteria, by design. Among the 27
cross-sectional studies, all except 9 studies had a control group,
5 studies used a matched control sample, 13 studies adjusted
analyses for relevant covariates, and all except 6 studies reported
cardiovascular risk factors. Among the 65 longitudinal studies, all
Table 2 Longitudinal studies: characteristics of included studies and samples (continued)
Study Country
No.
cases
No.
controls
Period of
data collection
SMI
deﬁnition Inclusion criteria for cases
No.
covariates
Lemogne et al84 France 4,336 16,621 1990-2010 ICD-9,10 Depression or severe mental illness
(bipolar disorder, psychosis)
6
Li et al85 Taiwan 1,003 4,012 1996-2009 ICD-9 Major depressive disorder 6
Lin et al86 Taiwan 7,353 22,059 2000-2006 ICD-9 Schizophrenia 8
Lin et al87 Taiwan 2,289 16,413 1998-2003 ICD-9 Bipolar disorder 10
Lin et al88 Taiwan 5,001 10,002 1998-2003 ICD-9 Schizophrenia, <45 years 9
Maina et al89 Italy 309 - 2003-2011 DSM-IV Bipolar disorder -
McDermott et al90 USA 503 2,083 1990-2003 ICD-9 Schizophrenia or severe mental illness 9
Murray-Thomas et al91 UK 232,132 193,920 1997-2001 ICD-10 Schizophrenia, bipolar disorder or major
depressive disorder
2
Olfson et al92 USA 1,138,853 - 2001-2007 ICD-10 Schizophrenia, 20-64 years 4
Osborn et al93 UK 38,824 - 1995-2010 Medical
records
Bipolar disorder or severe mental illness,
30-90 years
-
Pratt et al94 USA 73 1,107 1981-1994 DSM-III Major depressive disorder 11
Prieto et al95 USA 334 334 1966-1996 DSM-IV Bipolar disorder 4
Rahman et al96 Sweden 6,822 29,832 1998-2002 ICD-7,8,9,10 Major depressive disorder, twin population
study
7
Ramsey et al97 USA 129 1,339 1981-1982 DSM-III Bipolar disorder or major depressive disorder 6
Saint Onge et al98 USA 548 10,821 1999-2006 ICD Major depressive disorder 11
Scherrer et al99 USA 77,568 214,749 1999-2007 ICD-9 Major depressive disorder, 25-80 years 4
Schoepf & Heun100 UK 1,418 14,180 2000-2012 ICD-10 Schizophrenia, inpatients -
Schoepf et al101 UK 621 6,210 2000-2012 ICD-10 Bipolar disorder -
Shah et al102 USA 538 7,103 1988-2006 DSM-III Major depressive disorder or bipolar
disorder, 17-39 years
14
Stewart et al103 USA 235 - NA ICD-9 Major depressive disorder -
Surtees et al104 UK 3,057 16,592 1996-2008 DSM-IV Major depressive disorder, 45-80 years 11
Ting et al105 China 153 7,682 1996-2008 DSM-IV Major depressive disorder with diabetes 18
Torniainen et al106 Sweden 21,492 214,920 2006-2015 ICD-10 Schizophrenia, 17-65 years 2
Tsai et al107 Taiwan 80,569 241,707 1999-2003 ICD-9 Schizophrenia 8
Tsan et al108 USA 49,173 - 2002-2009 ICD-9 Schizophrenia -
van Marwijk et al109 The Netherlands 143 139 2002-2003 DSM-IV Major depressive disorder, >55 years -
Weeke et al110 Denmark 3,795 - 1950-1957;
1969-1977
ICD-8 Bipolar disorder -
Westman et al111 Sweden 17,101 10,631,208 1987-2006 ICD-10 Bipolar disorder 3
Wu et al112 Taiwan 16,821 67,284 1999-2010 ICD-9 Bipolar disorder 9
Wu et al113 Taiwan 70,225 207,592 1996-2007 ICD-9 Schizophrenia or bipolar disorder 8
SMI – severe mental illness, RDC – Research Diagnostic Criteria
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Table 5 Quality assessment of included studies
Study
Clear diagnostic
criteria
Control
group
Matched
controls
Coavariate adjusted
analyses
Reported cardiovascular
risk factors at baseline
Follow-up at
least 5 years
Cross-sectional studies
Beyer et al22 Y N N N Y N
Bresee et al23 Y Y N Y Y N
Bresee et al24 Y Y N Y Y N
Chen et al25 Y N N N Y N
Curkendall et al26 Y Y Y Y Y N
Devantier et al27 Y Y Y N Y N
Hagg et al28 Y N N N Y N
Herbst et al29 Y Y N Y N N
Huang et al30 Y Y N Y Y N
Hyde et al31 Y N N N Y N
Kilbourne et al32 Y N N N Y N
Kilbourne et al33 Y Y N Y Y N
Lindegard34 Y Y N N N N
Maina et al35 Y N N N Y N
Morden et al36 Y Y Y Y Y N
Munoli et al37 Y N N N Y N
Nielsen et al38 Y N N N Y N
Niranjan et al39 Y Y N Y Y N
Oreski et al40 Y Y N N Y N
Prieto et al41 Y N N N Y N
Scherrer et al42 Y Y N N N N
Scott et al43 Y Y N Y N N
Shen et al44 Y Y Y Y Y N
Smith et al45 Y Y N Y Y N
Smith et al46 Y Y N Y Y N
Swain et al47 Y Y N Y N N
Zilkens et al48 Y Y Y N N N
Longitudinal studies
Almeida et al49 Y Y Y N Y Y
Bremmer et al50 Y Y Y N Y Y
Butnoriene et al51 Y Y Y N N Y
Callaghan et al52 Y Y Y Y Y N
Callaghan et al53 Y Y Y Y Y N
Carney et al54 Y Y Y N Y N
Chen et al55 Y Y Y Y Y Y
Clouse et al56 Y Y Y N Y Y
Coryell et al57 Y Y N N N Y
Crump et al58 Y Y Y N N Y
Crump et al59 Y Y Y N Y Y
Davis et al60 Y Y Y N Y N
Davydow et al61 Y Y Y N N Y
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Table 5 Quality assessment of included studies (continued)
Study
Clear diagnostic
criteria
Control
group
Matched
controls
Coavariate adjusted
analyses
Reported cardiovascular
risk factors at baseline
Follow-up at
least 5 years
Enger et al62 Y Y Y Y Y N
Fiedorowicz et al63 Y Y Y N Y Y
Filik et al64 Y Y Y N Y N
Fors et al65 Y Y Y Y N Y
Gasse et al66 Y Y Y N N Y
Goldstein et al67 Y Y Y N Y N
Healy et al68 Y Y N N N Y
Hendrie et al69 Y Y Y N Y Y
Hou et al70 Y Y N N N Y
Hsieh et al71 Y Y N N N N
Huang et al72 Y Y Y Y Y Y
Ifteni et al73 Y Y N N N Y
Jakobsen et al74 Y Y Y Y N Y
Janszky et al75 Y Y Y N Y Y
Jokinen & Nordstrom et al76 Y Y N N N Y
Joukamaa et al77 Y Y Y N N Y
Kendler et al78 Y Y Y N N Y
Kiviniemi et al79 Y Y N N N Y
Lahti et al80 Y Y Y N Y Y
Lan et al81 Y Y N N Y Y
Laursen et al82 Y Y Y N N Y
Laursen et al83 Y Y Y N N Y
Lemogne et al84 Y Y Y N Y Y
Li et al85 Y Y Y Y Y Y
Lin et al86 Y Y Y Y Y Y
Lin et al87 Y Y Y Y Y Y
Lin et al88 Y Y Y Y Y Y
Maina et al89 Y Y N N N Y
McDermott et al90 Y Y Y N N Y
Murray-Thomas et al91 Y Y Y N N N
Olfson et al92 Y Y N N N Y
Osborn et al93 Y Y Y N Y Y
Pratt et al94 Y Y Y N Y Y
Prieto et al95 Y Y Y Y Y Y
Rahman et al96 Y Y Y Y Y N
Ramsey et al97 Y Y Y N Y Y
Saint Onge et al98 Y Y Y N Y Y
Scherrer et al99 Y Y Y N Y Y
Schoepf & Heun100 Y Y Y Y N Y
Schoepf et al101 Y Y Y Y Y Y
Shah et al102 Y Y Y N Y Y
Stewart et al103 Y Y N N N Y
Surtees et al104 Y Y Y N N Y
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had a control group, which was matched in all but 12 studies,
only 19 studies adjusted for covariates, 38 studies reported on
cardiovascular risk factors, and all except 12 studies had a
follow-up of at least 5 years.
Regional CVD prevalence, incidence and
longitudinal risk
Raw CVD prevalence and incidence rates consistently in-
creased from Asia, through Europe and North America, to
Oceania (Asia: 5.4% and 2.6%; Europe: 9.7% and 3.4%; North
America: 14.6% and 4.6%; Oceania: 20.6% and 26.3%; p<0.0001
for both prevalence and incidence). However, when comparing
CVD risk in SMI patients in each region with their respective
control groups, there was no statistically signiﬁcant difference
anymore across regions, with both RRs and adjusted HRs show-
ing comparably increased CVD incidence risk in the SMI popu-
lation (RRs ranging from 1.17 in Europe to 1.63 in Asia, p50.08;
and HRs ranging from 1.58 in Oceania to 1.88 in both Europe
and North America, p50.29) (Table 6). There were insufﬁcient
numbers of studies to perform this analysis for adjusted ORs
Table 5 Quality assessment of included studies (continued)
Study
Clear diagnostic
criteria
Control
group
Matched
controls
Coavariate adjusted
analyses
Reported cardiovascular
risk factors at baseline
Follow-up at
least 5 years
Ting et al105 Y Y Y N Y Y
Torniainen et al106 Y Y Y Y N Y
Tsai et al107 Y Y Y Y Y Y
Tsan et al108 Y Y N N Y Y
van Marwijk et al109 Y Y Y Y Y N
Weeke et al110 Y Y N N N N
Westman et al111 Y Y Y N N Y
Wu et al112 Y Y Y Y Y Y
Wu et al113 Y Y Y N Y Y
N – no, Y – yes
Table 6 Prevalence and incidence of cardiovascular disease (CVD) in severe mental illness stratiﬁed by region
Regional strata Analysis details
Prevalence
of CVD
Incidence
of CVD
Risk ratios
for incident
CVD
Adjusted hazard ratios
for incident CVD
Asia Pooled estimate, % (95% CI) 5.4 (4.3-6.7) 2.6 (1.9-3.6) 1.63 (1.31-2.04) 1.75 (1.38-2.22)
p value <0.0001 <0.0001 <0.0001 <0.0001
Heterogeneity, I2 (p value) 98 (<0.0001) 100 (<0.0001) 99 (<0.0001) 96 (<0.0001)
No. comparisons 8 12 9 10
Europe Pooled estimate, % (95% CI) 9.7 (6.5-14.2) 3.4 (2.2-5.3) 1.17 (0.96-1.42) 1.88 (1.44-2.46)
p value <0.0001 <0.0001 0.11 <0.0001
Heterogeneity, I2 (p value) 97 (<0.0001) 100 (<0.0001) 97 (<0.0001) 96 (<0.0001)
No. comparisons 9 35 20 22
North America Pooled estimate, % (95% CI) 14.6 (12.0-17.7) 4.6 (3.4-6.2) 1.39 (0.91-2.12) 1.88 (1.62-2.19)
p value <0.0001 <0.0001 0.13 <0.0001
Heterogeneity, I2 (p value) 97 (<0.0001) 100 (<0.0001) 97 (<0.0001) 62 (0.003)
No. comparisons 17 15 11 11
Oceania Pooled estimate, % (95% CI) 20.6 (10.9-35.4) 26.3 (24.1-28.6) 1.52 (1.40-1.66) 1.58 (1.41-1.78)
p value <0.0001 <0.0001 <0.0001 <0.0001
Heterogeneity, I2 (p value) 97 (<0.0001) 100 (<0.0001) 0 (0.72) 0 (0.84)
No. comparisons 4 3 3 3
p (difference between regions) <0.0001 <0.0001 0.08 0.29
World Psychiatry 16:2 - June 2017 175
regarding prevalence rates across regions, or for adjusted ORs,
RRs or HRs pertaining to speciﬁc CVD subgroups.
Meta-regression
Due to heterogeneous or partial reporting of possible mod-
erator variables in the included studies, all meta-regression
analyses were based on a much reduced number of studies.
Hence, all analyses were less powered in comparison with the
large sets of data used for cross-sectional prevalence and lon-
gitudinal incidence analyses. Nonetheless, CVD incidence
increased signiﬁcantly with a higher percentage of patients
using antipsychotics (12 studies; b50.04, 95% CI: 0.01-0.08,
p50.008), higher baseline body mass index in patients vs. con-
trols (6 studies; b50.24, 95% CI: 0.06-0.42, p50.008), and
higher CVD prevalence at baseline in patients vs. controls (7
studies; b50.07, 95% CI: 0.01-0.14, p50.03). CVD prevalence
increased in more recent studies (38 studies; b50.07, 95% CI:
0.02-0.12, p50.007), whereas the same was not true for CVD
incidence (65 studies; b5–0.02, 95% CI5–0.07 to 0.01, p50.21).
DISCUSSION
To our knowledge, this is the ﬁrst large scale meta-analysis
providing comprehensive quantitative data on the prevalence
and incidence of CVD in people with SMI, including both
pooled data and comparisons across CVD and SMI diagnostic
subgroups. Our results establish that approximately 10% of
people with SMI with a mean age of 50 years have at least one
comorbid CVD. Moreover, our longitudinal analysis docu-
ments a 3.6% incidence rate of CVD during a median of 8.4
years of follow-up. Patients with SMI show a 53% higher risk
for having CVD, a 78% higher risk for developing CVD, and an
85% higher risk of death from CVD compared to the regionally
matched general population.
This study provides a worldwide epidemiologic representa-
tion of CVD prevalence and incidence rates in SMI, reporting
the lowest absolute prevalence and incidence in Asia, increas-
ing through Europe and North America, and reaching the
highest levels in Oceania. However, in analyses with sufﬁcient
numbers of available studies, neither RRs nor adjusted HRs
indicated signiﬁcantly different CVD incidence risk across
regions, meaning that SMI patients are at an increased risk
across the world and that CVD risk-reducing interventions in
SMI are needed with the same urgency across all regions of
the world. Moreover, while the prevalence and incidence of
each CVD in people with SMI show someminor variations, peo-
ple with major depressive disorder, bipolar disorder and schizo-
phrenia are clearly all at an increased risk of CVD-related deaths
compared to population-stratiﬁed controls, calling for urgent
action.
We were able to identify some important and actionable
moderators of increased CVD risk, including antipsychotic
use, elevated body mass index and elevated baseline CVD.
Based on these results, it is imperative that clinicians: a) only
utilize antipsychotics, particularly for non-psychotic condi-
tions, when alternative treatment options with lower CVD risk
potential have been tried sufﬁciently; and b) screen for and
manage emerging and existing CVDs as well as their risk fac-
tors, including weight gain and elevated body mass index. Our
data, adding to research demonstrating a signiﬁcantly higher
prevalence of metabolic syndrome in people with SMI com-
pared to controls114, clearly suggest there is an urgent need to
prevent and manage CVD risk in this population.
Our results demonstrating a higher CVD prevalence in SMI
populations versus controls in more recent studies are also
concerning, as they support accumulating data indicating that
secondary prevention has been much less successful in the
SMI population that in the general population, leading to a
widening of the mortality gap in recent years49,115,116. Our
ﬁndings conﬁrm prior reports that antipsychotic medication
use is associated with higher CVD risk13,117,118. However, due
to limitations in the published data, we were unable to explore
variations in CVD risk proﬁles between different antipsychotic
medications13,117-120. Previous research has suggested that the
highest cardio-metabolic risks are associated with clozapine
and olanzapine, whilst the lowest risk is with aripiprazole,
ziprasidone, lurasidone, amisulpride and high potency typical
antipsychotics13,117-122. However, in this context it is also
important to note that antipsychotic medications can decrease
CVD-related mortality, as reported for example in Finnish79
and Swedish123 national database studies, that are highly gen-
eralizable. These data underscore that symptom control and
functional improvement beneﬁt both psychiatric and overall
health, as severe psychiatric illness negatively affects lifestyle
behaviors, medical care seeking and adherence to medical
treatments. Thus, beneﬁts of improved psychiatric status with
antipsychotics and other psychotropic agents need to be care-
fully weighed against their potential for elevated cardiometa-
bolic risk, which differs across available agents13,117.
Since antipsychotic medication use moderates CVD risk and
since antipsychotics are increasingly used as ﬁrst line treatments
for much more prevalent non-psychotic conditions, including
bipolar disorder124 and major depressive disorder with subopti-
mal response to antidepressant treatment125, the pool of people
at an increased CVD risk is greatly enlarged. Therefore, research
on the underlying mechanisms for the increased CVD risk after
pharmacotherapy initiation is even more urgently needed to
developmore effective and targeted preventive and intervention-
al treatments. Studies should also examine whether different
clinical subtypes of depression (i.e., melancholic, psychotic,
atypical or undifferentiated) and bipolar disorder (e.g., type 1 or
2, cyclothymic disorder), certain mood states (manic, depressive,
mixed or euthymic), or different antipsychotics, antidepressants
or mood stabilizers13 signiﬁcantly moderate CVD risk.
Furthermore, the pathophysiology underlying the associa-
tion between SMI and CVD risk is complex and not well
understood, clearly requiring further investigation. Emerging
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evidence suggests that SMI and CVD share pathophysiological
features, including hypothalamic-pituitary-adrenal and mito-
chondrial dysfunction, peripheral immune activation, neuro-
inﬂammation, oxidative and nitrosative stress, as well as com-
mon genetic links and epigenetic interactions126. However,
since these different mechanisms probably interact, research
that integrates these pathways is urgently needed. Beyond
mechanistic evaluations, such studies also need to investigate
the general and speciﬁc effects of physical health improve-
ments on SMI outcomes.
Future research should also investigate optimal monitoring
regimens across stratiﬁed patient subgroups as well as the most
effective timing and efﬁcacy of primary, secondary and tertiary
preventive interventions120,127. In this regard, studies should
comprehensively assess relevant moderator and mediator varia-
bles of CVD risk, including type and duration of speciﬁc psy-
chotropic medications use, physical activity (including using
passive monitoring via actimetry or mobile phone technology),
diet, smoking, body mass index, personal and family history of
CVD, in order to identify subgroups of patients who may require
different monitoring and or interventions schemes. Long-term
follow-up studies are also required to accurately document the
emergence of more distal physical and mental health as well as
health economic outcomes in relationship to the early identiﬁ-
cation and management of CVD risk factors and manifest CVD
conditions in people with SMI.
Finally, since people with SMI engage in unhealthy lifestyle
and often take psychotropic medication for extensive periods,
long-term follow-up studies are needed that assess whether
current predictor models based on the magnitude of tradition-
al CVD risk factor effects observed in the general population
apply or need to be adjusted for the SMI population93, in
whom CVD risk factors also emerge at a far earlier age117,128.
While this is the most comprehensive meta-analysis of CVD
risk in people with SMI conducted to date, we acknowledge
several limitations that are largely related to factors in the pri-
mary data. First, lifestyle behavior information (e.g., physical
activity) was inadequately reported, precluding meta-analytic
assessment of these important factors as moderating or medi-
ating variables. People with SMI are less likely than the general
population to engage in physical activity and have higher lev-
els of sedentary behaviour129, smoke more130, consume diets
that are high in saturated fats and reﬁned sugars, while being
low in fruit and vegetables131, all factors relevant for CVD risk.
Second, variables such as clinical subtypes of major depressive
disorder and bipolar disorder, negative symptom severity in
people with schizophrenia, and concomitant or previous use
of speciﬁc antipsychotics, antidepressants and mood stabil-
izers were not reported or were insufﬁciently reported or con-
trolled for in most available studies. Third, as expected when
combining observational data132, many of the results were
moderately to highly heterogeneous. However, in accordance
with the MOOSE guidelines133, we conducted meta-regression
analyses and were able to explain some of the observed het-
erogeneity. In addition, all of our results remained robust after
adjustment for potential publication bias with the trim and ﬁll
analysis.
In conclusion, SMIs pooled together were signiﬁcantly
associated in cross-sectional studies with CVD, coronary heart
disease, cerebrovascular disease and CVD-related death. Addi-
tionally, in longitudinal studies, each speciﬁc diagnostic SMI
group was signiﬁcantly associated with CVD and CVD-related
death. Furthermore, schizophrenia was associated with coro-
nary heart disease and cerebrovascular disease, while bipolar dis-
order was associated with congestive heart failure, and major
depressive disorder was associated with coronary heart disease,
cerebrovascular disease, and congestive heart failure.
Importantly, our data conﬁrm that CVDs are associated with
an increased risk of mortality in people with SMI, which to a
large part explains the shortened life expectancy of people with
SMI compared to the general population2,4,5. Furthermore, we
showed geographical variations in raw CVD prevalence and inci-
dence risk in SMI populations, but no signiﬁcant regional vari-
ance in the difference in CVD risk compared to the region-
speciﬁc general population. Finally, the fact that antipsychotic
use, higher body mass index and baseline CVD signiﬁcantly
increased the risk for CVD morbidity and mortality underscores
the urgent need to limit antipsychotic use to those populations
truly requiring them, choosing the lowest risk antipsychotic
agents ﬁrst in the treatment algorithm, screening all SMI patients
regularly for CVD risk factors and conditions, and addressing any
identiﬁed abnormalities aggressively.
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